论文部分内容阅读
目的探讨非小细胞肺癌(NSCLC)患者X线修复交叉互补基因1(XRCC1)单核苷酸多态性与铂类药物化疗前后外周血细胞参数变化的关系。方法化疗前采集外周血采用焦磷酸基因测序法检测54例非小细胞肺癌患者XRCC1基因的Arg194Trp、Arg399GIn基因多态性的分型,观察铂类药物化疗前后外周血细胞计数变化的情况。结果 XRCC1194 Arg/Trp+Trp/Trp基因型患者在化疗后第7 d、第10 d和第13 d,其白细胞、中性粒细胞、淋巴细胞、红细胞、血小板、血小板比积计数与治疗前差异有统计学意义(P<0.05);XRCC1 399GIn/GIn基因型患者在化疗后第7 d、第10 d和第13 d,其白细胞、中性粒细胞、单核细胞、淋巴细胞、红细胞、血小板、血小板比积与治疗前差异亦有统计学意义(P<0.05);XRCC1194 Arg/Arg基因型患者第7、10、13 d只有淋巴细胞计数与治疗前差异有统计学意义(P<0.05);XRCC1 399Arg/GIn+Arg/Arg基因型患者化疗前后外周血细胞计数差异无统计学意义(P>0.05)。结论 XRCC1 399GIn/GIn基因型患者化疗对外周血细胞的影响最大;其次是XRCC1 194Arg/Trp+Trp/Trp基因型患者化疗对外周血细胞的影响较大;XRCC1 194 Arg/Arg基因型患者只有淋巴细胞计数下降;XRCC1 399Arg/GIn+Arg/Arg基因型患者化疗前后外周血细胞计数下降无关。临床医师有望通过检测患者的XRCCI基因多态性来预测应用铂类药物的毒副作用。
Objective To investigate the relationship between XRCC1 polymorphisms and peripheral blood cell parameters before and after platinum-based chemotherapy in patients with non-small cell lung cancer (NSCLC). Methods Peripheral blood samples were collected before chemotherapy. The genotypes of Arg194Trp and Arg399Gln polymorphisms of XRCC1 gene in 54 patients with non-small cell lung cancer were detected by pyrosequencing. The changes of peripheral blood cell counts before and after platinum-based chemotherapy were observed. Results On the 7th day, the 10th day and the 13th day after chemotherapy, the counts of white blood cells, neutrophils, lymphocytes, erythrocytes, platelets and platelets in XRCC1194 Arg / Trp + Trp / Trp genotype patients were significantly different from those before treatment (P <0.05). In the patients with XRCC1 399GIn / GIn genotype, white blood cells, neutrophils, monocytes, lymphocytes, erythrocytes and platelets were detected on the 7th day, the 10th day and the 13th day after chemotherapy (P <0.05). There was significant difference between the XRCC1194 Arg / Arg genotypes on the 7th, 10th, 13th and the 13th days after treatment (P <0.05) There was no significant difference in peripheral blood count before and after chemotherapy for XRCC1 399Arg / GIn + Arg / Arg genotypes (P> 0.05). Conclusion The chemotherapy of XRCC1 399GIn / GIn genotype patients has the greatest impact on the peripheral blood cells; followed by XRCC1 194Arg / Trp + Trp / Trp genotype chemotherapy patients have a greater impact on peripheral blood cells; XRCC1 194 Arg / Arg genotype patients only lymphocyte count Decreased; there was no difference in peripheral blood cell counts before and after chemotherapy in patients with XRCC1 399Arg / GIn + Arg / Arg genotype. Clinicians are expected to predict the toxic side effects of platinum-based drugs by detecting the patient’s XRCCI gene polymorphism.